Company Overview - Tyra Biosciences is a biotechnology company focused on precision oncology and rare genetic disease therapeutics, utilizing structure-based drug design to tackle resistance mechanisms in cancer treatment [6] - The company specializes in FGFR-driven diseases, aiming to meet unmet medical needs with differentiated small molecule therapies [6] - Tyra's proprietary SNAP platform allows for rapid iteration and optimization, providing a competitive edge in early-stage drug discovery [6] Financial Summary - As of November 21, 2025, Tyra Biosciences has a market capitalization of $1.352 billion and a stock price of $20.25 [4] - The company reported a net income of -$111.68 million (TTM) and a 1-year price change of 37.5% [4] - The stock has increased over 80% year to date, outperforming the S&P 500's total return of 18.4% during the same period [10] Recent Transactions - On November 21, 2025, Director Robert J. More sold 246,871 shares for a transaction value of $5.0 million, as part of a Rule 10b5-1 trading plan [2][3] - Post-transaction, More retains nearly 4 million shares valued at approximately $77.6 million [7][9] Product Pipeline - The company is developing targeted therapies for cancer and genetic diseases, with its lead candidate TYRA-300 focused on FGFR3-driven muscle invasive bladder cancer [8] - The pipeline also includes treatments for FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-related achondroplasia, FGFR4-related cancers, and RET-driven conditions [8] - Revenue generation is anticipated from future product approvals and commercialization [8]